Quris to launch AI-based clinical trial for fragile X syndrome in 2022

A candidate therapy for fragile X syndrome – developed using Quris’ bio-artificial intelligence clinical prediction platform – will enter clinical trials in 2022, the company said.

Quris uses the power of artificial intelligence (AI) combined with a “patient-on-a-chip” platform to predict the safety and potential efficacy of drug candidates before they are used in human trials.

“We are at the crossroads of modernizing drug discovery. I think the Quris platform could be of significant value to pharmaceutical companies and the health of society as a whole, ”said Robert S. Langer, co-founder of Moderna, in a press release. Langer sits on the scientific advisory board of Quris.

This approach, according to Quris, bypasses the need for animal models that fail to replicate the characteristics of human disease and should reduce both the risks and costs associated with failed clinical trials.

recommended reading

“Simply put: we are not mice, so what works in animal trials is not an appropriate indicator of what will work for people,” added Aaron Ciechanover, MD and Nobel Prize winner. “By using a revolutionary way to test drug candidates on miniaturized on-chip patients, Quris can demonstrate their safety and efficacy, or lack thereof, through preliminary on-chip clinical trials. This has never been done before, and Quris is leading the way.

Isaac Bentwich, MD, CEO of Quris, said: “Intensely competitive and extremely expensive drug discovery based on AI has become the main frontier of pharmaceutical innovation. But as AI applications in the pharmaceutical industry have grown, a critical piece needed to solve the drug discovery puzzle has disappeared and most new drugs still fail clinical trials, costing pharmaceutical companies. over $ 30 billion a year.

“Quris is the first AI platform to predict which drug candidates will work safely in humans, filling a critical gap in clinical prediction,” Bentwich added.

Quris’ Patients-on-a-Chip Platform is the ultimate preclinical step before actual clinical trials in humans. For each particular disease, researchers use induced pluripotent stem cells (iPSCs) collected from patients to generate “patient-derived organs” or “patient-on-a-chip” in the lab (in vitro). These in vitro the platforms are then used to assess the safety and potential of candidate therapies.

IPSCs are derived from skin or blood cells that have been reprogrammed into a stem cell-like state, allowing the development of an unlimited source of almost all types of human cells.

Quris uses stem cell automation technology from the New York Stem Cell Foundation (NYSCF) Research Institute to develop an automated, self-paced AI platform that can better predict safety and efficacy of potential therapeutic candidates.

“We are on the cusp of a complete paradigm shift in drug testing and development,” said Susan L. Solomon, Founder and CEO of the NYSCF Research Institute.

“Our team of scientists are excited about the collaboration with Quris, which leverages a powerful synergy between our stem cell automation technology and Quris’ impressive AI-Chip-on-Chip platform and technology team,” to better predict the clinical safety of drugs for patient individuals, ”added Salomon. Solomon joins the Quris Advisory Board.

Quris also announced $ 9 million seed funding led by Judith Richter, PhD, and Kobi Richter, PhD, co-founders of Medinol, with participation from Moshe Yanai, an Israeli entrepreneur, and strategic angel investors.

About Margie Peters

Check Also

Global Biosimilar Monoclonal Antibody Market Projected

Visiongain has released a new report titled Biosimilar monoclonal antibodies 2022-2032. It includes biosimilar monoclonal …